Symbols / TPST Stock $1.79 -0.56% Tempest Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
TPST (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Matthew Angel Ph.D.
Exch · Country NCM · United States
Market Cap 25.68M
Enterprise Value 26.11M
Income -26.26M
Sales —
FCF (ttm) -17.59M
Book/sh 1.35
Cash/sh 0.54
Employees 4
Insider 10d —
IPO Nov 12, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.48
PEG —
P/S —
P/B 1.32
P/C —
EV/EBITDA -0.99
EV/Sales —
Quick Ratio 2.33
Current Ratio 2.50
Debt/Eq 122.09
LT Debt/Eq —
EPS (ttm) -6.33
EPS next Y -1.21
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-30
ROA -56.86%
ROE -203.63%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 14.34M
Shs Float 9.27M
Insider Own 35.37%
Instit Own 29.41%
Short Float 11.10%
Short Ratio 2.06
Short Interest 640.47K
52W High 12.23
vs 52W High -85.36%
52W Low 1.50
vs 52W Low 19.33%
Beta -1.89
Impl. Vol. —
Rel Volume 0.48
Avg Volume 203.39K
Volume 98.35K
Target (mean) $11.00
Tgt Median $11.00
Tgt Low $11.00
Tgt High $11.00
# Analysts 1
Recom None
Prev Close $1.80
Price $1.79
Change -0.56%
About

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.00
Mean price target
2. Current target
$1.79
Latest analyst target
3. DCF / Fair value
$-22.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.79
Low
$11.00
High
$11.00
Mean
$11.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-22 up HC Wainwright & Co. Neutral → Buy $11
2025-04-10 down Scotiabank Sector Outperform → Sector Perform $9
2025-04-10 down HC Wainwright & Co. Buy → Neutral $16
2025-03-28 main Scotiabank Sector Outperform → Sector Outperform $7
2025-03-28 main HC Wainwright & Co. Buy → Buy $16
2024-11-13 main Piper Sandler Overweight → Overweight $5
2024-11-13 reit HC Wainwright & Co. Buy → Buy $47
2024-10-10 reit HC Wainwright & Co. Buy → Buy $47
2024-08-15 reit HC Wainwright & Co. Buy → Buy $47
2024-06-21 reit Piper Sandler Overweight → Overweight $8
2024-06-20 reit HC Wainwright & Co. Buy → Buy $47
2024-05-13 reit HC Wainwright & Co. Buy → Buy $47
2024-05-10 reit HC Wainwright & Co. Buy → Buy $47
2024-03-20 reit HC Wainwright & Co. Buy → Buy $47
2024-03-14 init Scotiabank — → Sector Outperform $13
2024-03-13 init Scotiabank — → Sector Outperform $13
2024-03-12 main HC Wainwright & Co. Buy → Buy $47
2024-02-08 init Jefferies — → Buy $15
2023-10-11 main HC Wainwright & Co. Buy → Buy $47
2023-08-11 reit HC Wainwright & Co. Buy → Buy $35
News
RSS: Latest TPST news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-24 ANGEL MATTHEW Chief Executive Officer — 231,482 $1.75 $405,094
2024-08-12 VERSANT VENTURE CAPITAL VI, L.P. Beneficial Owner of more than 10% of a Class of Security — 787,999 $1.10 $967,033
2024-07-03 BRADY STEPHEN R Chief Executive Officer — 35,000 $2.11 $73,850
2024-06-28 TROJANOWSKI JUSTIN Officer — 7,500 $2.16 $16,200
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
26.57
-36.77%
42.03
+44.14%
29.16
-15.83%
34.64
Research And Development
12.61
-55.73%
28.48
+62.74%
17.50
-22.32%
22.53
Selling General And Administration
13.97
+3.09%
13.55
+16.22%
11.66
-3.75%
12.11
General And Administrative Expense
13.97
+3.09%
13.55
+16.22%
11.66
-3.75%
12.11
Other Gand A
13.97
+3.09%
13.55
+16.22%
11.66
-3.75%
12.11
Total Expenses
26.57
-36.77%
42.03
+44.14%
29.16
-15.83%
34.64
Operating Income
-26.57
+36.77%
-42.03
-44.14%
-29.16
+15.83%
-34.64
Total Operating Income As Reported
-26.57
+36.77%
-42.03
-44.14%
-29.16
+15.83%
-34.64
EBITDA
-25.79
+35.75%
-40.14
-45.11%
-27.66
+17.31%
-33.45
Normalized EBITDA
-25.79
+35.75%
-40.14
-45.11%
-27.66
+17.31%
-33.45
Reconciled Depreciation
0.27
-31.62%
0.39
+2.10%
0.38
-40.28%
0.64
EBIT
-26.05
+35.71%
-40.53
-44.52%
-28.04
+17.74%
-34.09
Net Income
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Pretax Income
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Net Non Operating Interest Income Expense
0.31
+71.04%
0.18
+154.79%
-0.33
+67.19%
-1.02
Interest Expense Non Operating
0.21
-84.27%
1.32
-9.18%
1.45
-10.44%
1.62
Net Interest Income
0.31
+71.04%
0.18
+154.79%
-0.33
+67.19%
-1.02
Interest Expense
0.21
-84.27%
1.32
-9.18%
1.45
-10.44%
1.62
Interest Income Non Operating
0.52
-65.31%
1.50
+34.44%
1.11
+85.83%
0.60
Interest Income
0.52
-65.31%
1.50
+34.44%
1.11
+85.83%
0.60
Other Income Expense
—
—
0.01
+129.41%
-0.05
Other Non Operating Income Expenses
—
—
0.01
+129.41%
-0.05
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Net Income From Continuing Operation Net Minority Interest
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Net Income From Continuing And Discontinued Operation
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Net Income Continuous Operations
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Normalized Income
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Net Income Common Stockholders
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Diluted EPS
—
-19.50
+21.47%
-24.83
+38.19%
-40.17
Basic EPS
—
-19.50
+21.47%
-24.83
+38.19%
-40.17
Basic Average Shares
—
3.38
+185.23%
1.19
+33.40%
0.89
Diluted Average Shares
—
3.38
+185.23%
1.19
+33.40%
0.89
Diluted NI Availto Com Stockholders
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
16.93
-59.19%
41.49
-19.60%
51.60
+11.96%
46.09
Current Assets
8.27
-73.73%
31.47
-22.02%
40.36
+22.50%
32.95
Cash Cash Equivalents And Short Term Investments
7.71
-74.54%
30.27
-22.84%
39.23
+25.62%
31.23
Cash And Cash Equivalents
7.71
-74.54%
30.27
-22.84%
39.23
+25.62%
31.23
Receivables
—
—
0.00
-100.00%
0.45
Other Receivables
—
—
—
0.45
Prepaid Assets
0.21
-69.15%
0.67
-35.29%
1.04
+2.98%
1.01
Other Current Assets
0.35
-33.64%
0.54
+457.29%
0.10
-63.50%
0.26
Total Non Current Assets
8.66
-13.50%
10.01
-10.91%
11.24
-14.45%
13.14
Net PPE
8.14
-14.52%
9.53
-11.70%
10.79
-15.09%
12.71
Gross PPE
9.60
-11.53%
10.85
-8.19%
11.82
-16.02%
14.07
Accumulated Depreciation
-1.45
-10.08%
-1.32
-28.78%
-1.02
+24.69%
-1.36
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
9.95
-14.58%
11.65
Machinery Furniture Equipment
0.41
-20.38%
0.52
+4.63%
0.50
+3.97%
0.48
Other Properties
8.99
-11.28%
10.13
-8.63%
11.09
+944.77%
1.06
Leases
0.20
-1.49%
0.20
-14.47%
0.23
-73.36%
0.88
Other Non Current Assets
0.52
+6.60%
0.48
+8.26%
0.45
+4.43%
0.43
Total Liabilities Net Minority Interest
10.26
-54.11%
22.36
-9.96%
24.84
-11.23%
27.98
Current Liabilities
3.31
-76.69%
14.22
+51.10%
9.41
+29.33%
7.28
Payables And Accrued Expenses
1.98
-62.27%
5.24
+98.97%
2.63
-43.00%
4.62
Payables
1.04
-57.63%
2.45
+189.94%
0.84
-23.74%
1.11
Accounts Payable
1.04
-57.63%
2.45
+189.94%
0.84
-23.74%
1.11
Current Accrued Expenses
0.94
-66.36%
2.79
+55.94%
1.79
-49.09%
3.51
Pensionand Other Post Retirement Benefit Plans Current
0.15
-91.66%
1.76
+14.19%
1.54
+23.64%
1.25
Current Debt And Capital Lease Obligation
1.19
-83.50%
7.22
+37.92%
5.24
+270.63%
1.41
Current Debt
—
6.35
+48.28%
4.29
—
Other Current Borrowings
—
6.35
+48.28%
4.29
—
Current Capital Lease Obligation
1.19
+37.17%
0.87
-8.72%
0.95
-32.63%
1.41
Total Non Current Liabilities Net Minority Interest
6.95
-14.65%
8.14
-47.21%
15.42
-25.49%
20.70
Long Term Debt And Capital Lease Obligation
6.95
-14.65%
8.14
-47.21%
15.42
-25.49%
20.70
Long Term Debt
—
—
6.26
-39.60%
10.37
Long Term Capital Lease Obligation
6.95
-14.65%
8.14
-11.11%
9.16
-11.33%
10.33
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
6.67
-65.14%
19.13
-28.55%
26.77
+47.80%
18.11
Common Stock Equity
6.67
-65.14%
19.13
-28.55%
26.77
+47.80%
18.11
Capital Stock
0.01
+66.67%
0.00
-86.36%
0.02
+100.00%
0.01
Common Stock
0.01
+66.67%
0.00
-86.36%
0.02
+100.00%
0.01
Share Issued
4.93
+45.67%
3.38
+99.46%
1.70
+109.58%
0.81
Ordinary Shares Number
4.93
+45.67%
3.38
+99.46%
1.70
+109.58%
0.81
Additional Paid In Capital
240.03
+6.10%
226.23
+17.82%
192.01
+24.78%
153.87
Retained Earnings
-233.37
-12.68%
-207.11
-25.32%
-165.26
-21.72%
-135.77
Total Equity Gross Minority Interest
6.67
-65.14%
19.13
-28.55%
26.77
+47.80%
18.11
Total Capitalization
6.67
-65.14%
19.13
-42.10%
33.03
+15.98%
28.48
Working Capital
4.96
-71.28%
17.25
-44.26%
30.95
+20.56%
25.67
Invested Capital
6.67
-73.83%
25.48
-31.72%
37.32
+31.02%
28.48
Total Debt
8.14
-47.02%
15.37
-25.63%
20.66
-6.57%
22.11
Capital Lease Obligations
8.14
-9.65%
9.01
-10.89%
10.11
-13.89%
11.74
Net Tangible Assets
6.67
-65.14%
19.13
-28.55%
26.77
+47.80%
18.11
Tangible Book Value
6.67
-65.14%
19.13
-28.55%
26.77
+47.80%
18.11
Interest Payable
0.00
-100.00%
0.06
-47.79%
0.11
+16.49%
0.10
Notes Receivable
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-26.82
+18.79%
-33.03
-20.73%
-27.36
+11.96%
-31.07
Cash Flow From Continuing Operating Activities
-26.82
+18.79%
-33.03
-20.73%
-27.36
+11.96%
-31.07
Net Income From Continuing Operations
-26.26
+37.24%
-41.84
-41.88%
-29.49
+17.41%
-35.71
Depreciation Amortization Depletion
0.27
-31.62%
0.39
+2.10%
0.38
-40.28%
0.64
Depreciation
0.27
-31.62%
0.39
+2.10%
0.38
-40.28%
0.64
Depreciation And Amortization
0.27
-31.62%
0.39
+2.10%
0.38
-40.28%
0.64
Other Non Cash Items
1.19
-21.38%
1.51
-19.80%
1.88
+20.00%
1.57
Stock Based Compensation
3.12
-41.20%
5.30
+108.29%
2.55
+63.10%
1.56
Change In Working Capital
-5.13
-418.04%
1.61
+160.25%
-2.68
-408.41%
0.87
Change In Prepaid Assets
0.61
+659.09%
-0.11
-156.99%
0.19
-78.91%
0.92
Change In Payables And Accrued Expense
-4.88
-272.63%
2.82
+327.93%
-1.24
-185.21%
1.45
Change In Accrued Expense
-3.46
-384.09%
1.22
+224.90%
-0.98
-167.17%
1.45
Change In Payable
-1.41
-187.98%
1.60
+710.27%
-0.26
-26400.00%
0.00
Change In Account Payable
-1.41
-187.98%
1.60
+710.27%
-0.26
-26400.00%
0.00
Change In Other Current Liabilities
-0.87
+20.98%
-1.10
+32.50%
-1.63
-8.66%
-1.50
Investing Cash Flow
0.00
+100.00%
-0.43
-155.88%
-0.17
+69.75%
-0.56
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.43
-155.88%
-0.17
+69.75%
-0.56
Net PPE Purchase And Sale
0.00
+100.00%
-0.43
-155.88%
-0.17
+69.75%
-0.56
Purchase Of PPE
0.00
+100.00%
-0.43
-155.88%
-0.17
+69.75%
-0.56
Capital Expenditure
—
-0.43
-155.88%
-0.17
+69.75%
-0.56
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
4.26
-82.62%
24.50
-31.18%
35.60
+212.22%
11.40
Cash Flow From Continuing Financing Activities
4.26
-82.62%
24.50
-31.18%
35.60
+212.22%
11.40
Net Issuance Payments Of Debt
-6.43
-46.11%
-4.40
0.00
+100.00%
-4.74
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-6.43
-46.11%
-4.40
0.00
+100.00%
-4.74
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-6.43
-46.11%
-4.40
0.00
+100.00%
-4.74
Net Long Term Debt Issuance
-6.43
-46.11%
-4.40
0.00
+100.00%
-4.74
Net Common Stock Issuance
7.33
-74.37%
28.59
-19.69%
35.60
+301.78%
8.86
Proceeds From Stock Option Exercised
3.36
+993.16%
0.31
0.00
-100.00%
7.28
Net Other Financing Charges
—
—
—
—
Changes In Cash
-22.56
-151.74%
-8.96
-210.98%
8.07
+139.91%
-20.23
Beginning Cash Position
30.71
-22.59%
39.67
+25.56%
31.60
-39.03%
51.83
End Cash Position
8.15
-73.46%
30.71
-22.59%
39.67
+25.56%
31.60
Free Cash Flow
-26.82
+19.85%
-33.46
-21.56%
-27.53
+12.98%
-31.63
Interest Paid Supplemental Data
0.19
-83.69%
1.18
-5.76%
1.25
-18.84%
1.54
Income Tax Paid Supplemental Data
0.04
-20.37%
0.05
-71.73%
0.19
+961.11%
0.02
Change In Interest Payable
-0.06
-9.26%
-0.05
-437.50%
0.02
+106.25%
-0.26
Common Stock Issuance
7.33
-74.37%
28.59
-19.69%
35.60
+301.78%
8.86
Issuance Of Capital Stock
7.33
-74.37%
28.59
-19.69%
35.60
+301.78%
8.86
Net Preferred Stock Issuance
—
—
—
7.28
Preferred Stock Issuance
—
—
—
7.28
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category